Unibest
← Back to patent-cliff list

Rezafungin acetate

Tier C — Watch / trade

Rezafungin acetate

Seachaid Pharmaceuticals
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:1,3-beta-glucan synthase

Brand:Biafungin, REZZAYO

Indications (approved):侵袭性念珠菌病, Candidiasis, Candidaemia

Regional status

US
Approved
2023-03-22
EU
Approved
2023-12-22
China
Filed / under review
2025-02-26
Japan
-

Factories producing this API4

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

4 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Sign in to view factories →

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Rezafungin acetate?

Approved indications include: 侵袭性念珠菌病, Candidiasis, Candidaemia.

When does the Rezafungin acetate patent expire?

No public expiry year is available for Rezafungin acetate yet; this page updates once verified.

How do I get a quote for Rezafungin acetate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27